tiprankstipranks
VYNE Therapeutics initiated with a Buy at BTIG
PremiumThe FlyVYNE Therapeutics initiated with a Buy at BTIG
2M ago
VYNE Therapeutics Advances Clinical Pipeline in Q3 2024
Premium
Company Announcements
VYNE Therapeutics Advances Clinical Pipeline in Q3 2024
2M ago
VYNE Therapeutics reports Q3 EPS (29c) vs ($2.01) last year
Premium
The Fly
VYNE Therapeutics reports Q3 EPS (29c) vs ($2.01) last year
2M ago
VYNE Therapeutics announces granting of composition of matter patent for VYN202
PremiumThe FlyVYNE Therapeutics announces granting of composition of matter patent for VYN202
6M ago
VYNE Therapeutics announces appointment of Banerjee as SVP
Premium
The Fly
VYNE Therapeutics announces appointment of Banerjee as SVP
6M ago
VYNE Therapeutics announces dosing of first patients in Phase 1a trial of VYN202
Premium
The Fly
VYNE Therapeutics announces dosing of first patients in Phase 1a trial of VYN202
7M ago
Vyne Therapeutics Inc’s New Natural and Human Disruptions Risk – A Cause for Worry?
PremiumCompany AnnouncementsVyne Therapeutics Inc’s New Natural and Human Disruptions Risk – A Cause for Worry?
11M ago
VYNE Therapeutics files $250M mixed securities shelf
Premium
The Fly
VYNE Therapeutics files $250M mixed securities shelf
11M ago
VYNE Therapeutics expects cash to fund operations through 2025
Premium
The Fly
VYNE Therapeutics expects cash to fund operations through 2025
11M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100